GRK5 as a Novel Therapeutic Target for Immune Evasion in Testicular Cancer: Insights from Multi-Omics Analysis and Immunotherapeutic Validation
Open Access
- 21 July 2025
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 13 (7) , 1775
Abstract
Background: Personalized anti-tumor therapy that activates the immune response has demonstrated clinical benefits in various cancers. However, its efficacy against testicular cancer (TC) remains uncertain. This study aims to identify suitable patients for anti-tumor immunotherapy and to uncover potential therapeutic targets in TC for the development of tailored anti-tumor immunotherapy. Methods: Consensus clustering analysis was conducted to delineate immune subtypes, while weighted gene co-expression network analysis (WGCNA), least absolute shrinkage and selection operator (LASSO) regression, and support vector machine (SVM) algorithms were employed to evaluate the potential efficacy of anti-tumor immunotherapy. Candidate immunotherapy targets were systematically identified through multi-gene panel analyses and subsequently validated using molecular biology assays. A prioritized target emerging from cellular screening was further evaluated for its capacity to potentiate anti-tumor immunity. The therapeutic efficacy of this candidate was rigorously confirmed through a comprehensive suite of immunological experiments. Results: Following systematic screening of five candidate genes (WNT11, FAM181B, GRK5, FSCN1, and ECHS1), GRK5 emerged as a promising therapeutic target for immunotherapy based on its distinct functional and molecular associations with immune evasion mechanisms. Cellular functional assays revealed that GRK5 knockdown significantly attenuated the malignant phenotype of testicular cancer cells, as evidenced by reduced proliferative capacity and invasive potential. Complementary immunological validation established that specific targeting of GRK5 with the selective antagonist GRK5-IN-2 disrupts immune evasion pathways in testicular cancer, as quantified by T-cell-mediated cytotoxicity. Conclusions: These findings position GRK5 as a critical modulator of tumor-immune escape, warranting further preclinical exploration of GRK5-IN-2 as a candidate immunotherapeutic agent.Keywords
Funding Information
- Zhejiang Province Medical and Health Technology Plan Project (2024KY094, 2025C02055, Horizontal project: 491070-I22301)
- Key R&D Program of Zhejiang (2024KY094, 2025C02055, Horizontal project: 491070-I22301)
- mechanism of drug resistance and key treatment techniques for malignant tumors (2024KY094, 2025C02055, Horizontal project: 491070-I22301)
This publication has 37 references indexed in Scilit:
- Design, synthesis, and X-ray structural studies of a series of highly potent, selective, and drug-like G protein-coupled receptor kinase 5 inhibitorsEuropean Journal of Medicinal Chemistry, 2024
- European Association of Urology Guidelines on Testicular Cancer: 2023 UpdateEuropean Urology, 2023
- LAG3 and its emerging role in cancer immunotherapyClinical and Translational Medicine, 2021
- Comprehensive analysis of CTLA-4 in the tumor immune microenvironment of 33 cancer typesInternational Immunopharmacology, 2020
- Therapeutic strategies to remodel immunologically cold tumorsClinical & Translational Immunology, 2020
- Testicular germ cell tumor: a comprehensive reviewCellular and Molecular Life Sciences, 2019
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome AnalyticsCell, 2018
- Future of testicular germ cell tumor incidence in the United States: Forecast through 2026Cancer, 2017
- Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human CancerImmunity, 2013
- G-Protein Coupled Receptor Kinase 5 Regulates Prostate Tumor GrowthJournal of Urology, 2012